IVIG Delays Onset in a Mouse Model of Gerstmann-Sträussler-Scheinker Disease by Gu, Huiying et al.
IVIG Delays Onset in a Mouse Model of Gerstmann-Sträussler-
Scheinker Disease
Huiying Gu1, Yvonne Kirchhein1,2, Timothy Zhu1, Gang Zhao1,3, Hongjun Peng4, Eileen 
Du5, Junyi Liu6, James A. Mastrianni7, Martin R. Farlow1, Richard Dodel2, and Yansheng 
Du1,8
1Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
2Department of Neurology, Philipps-University Marburg, Marburg, Germany
3School of Basic Medical Sciences, Hubei University of Chinese Medicine, Wuhan, People’s 
Republic of China
4Department of Pediatrics, Jinling Hospital, Nanjing University School of Medicine, Nanjing 
210002, China
5Department of Psychology, Boston College, Chestnut Hill, MA 02467, USA
6Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University, Beijing 
100191, China
7Department of Neurology, University of Chicago, Chicago, IL 60637, USA
8Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical 
University, Tianjin 300070, China
Abstract
Our previous studies showed that intravenous immunoglobulin (IVIG) contained anti-Aβ 
autoantibodies that might be able to treat Alzheimer’s disease (AD). Recently, we identified and 
characterized naturally occurring autoantibodies against PrP from IVIG. Although autoantibodies 
in IVIG blocked PrP fibril formation and PrP neurotoxicity in vitro, it remained unknown whether 
IVIG could reduce amyloid plaque pathology in vivo and be used to effectively treat animals with 
prion diseases. In this study, we used Gerstmann-Sträussler-Scheinker (GSS)-Tg (PrP-A116V) 
transgenic mice to test IVIG efficacy since amyloid plaque formation played an important role in 
GSS pathogenesis. Here, we provided strong evidence that demonstrates how IVIG could 
significantly delay disease onset, elongate survival, and improve clinical phenotype in Tg (PrP-
A116V) mice. Additionally, in treated animals, IVIG could markedly inhibit PrP amyloid plaque 
formation and attenuate neuronal apoptosis at the age of 120 days in mice. Our results indicate that 
IVIG may be a potential, effective therapeutic treatment for GSS and other prion diseases.
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Introduction
Prion diseases, also known as transmissible spongiform en-cephalopathies (TSEs), are a 
group of rare progressive neurodegenerative disorders linked to the accumulation of 
misfolded, self-replicating, and proteinase K-resistant conformers, termed scrapie PrP 
(PrPSc) from the normal cellular prion protein (PrPC) [1]. They are characterized by 
spongiform degeneration of the central nervous system (CNS) consisting of neuronal death, 
insoluble prion amyloid aggregates, astrogliosis, and neuroinflammation [2]. TSEs caused 
by altered forms of PrP include scrapie in sheep and bovine spongiform encephalopathy in 
cattle, as well as the human forms Kuru, Creutzfeldt-Jakob disease (CJD and vCJD), and the 
Gerstmann-Sträussler-Scheinker (GSS) syndrome [3]. GSS is an inherited prion disease, 
typified by the onset of progressive ataxia (incoordination), the progression of dementia, and 
the presence of PrP amyloid deposits forming plaques in the brain. Recently, a GSS-Tg 
(PrP-A116V) transgenic mouse model was established and characterized [4].
The PrPSc aggregates in affected brain areas are thought to lead to neuronal dysfunction and 
neuronal death, which leads to clinical symptoms [3, 5, 6]. PrPSc represents a primary target 
for therapeutic strategies [7]. The expression of PrPC is not restricted only to the brain but 
also occurs in peripheral tissues including normal human lymphocytes, monocytes, 
neutrophils, and lymphoid cells [8–10]. In fact, PrPC expresses about four times more on 
activated lymphocytes than resting cells, and thus provides a potential reservoir for PrPSc 
replication [8]. Studies show that the latent stage of prion disease is characterized by 
accumulation of PrPSc in lymphatic organs such as the spleen, tonsils, lymph nodes, or gut 
before its accumulation in the CNS [11–13]. The spleen is thought to be the site for initial 
prion accumulation in bovine spongiform encephalopathy [14]. A number of studies show 
that spleen follicular dendritic cells (FDCs), stromal cells located in primary B cell follicles 
and germinal centers of lymphoid tissues, are the main site for prion replication [15]. 
Impaired neuroinvasion was observed in immunodeficient mice that lacked or had a 
temporary inactivation of FDCs [16–20]. Therefore, immunotherapy that targets peripheral 
lymphoid system could be effective in treating prion diseases.
Our previous studies indicated that intravenous immunoglobulin (IVIG) contained anti-Aβ 
autoantibodies or purified autoantibodies against Aβ, which could be used to treat 
Alzheimer’s disease (AD) [21–26]. Recently, we also detected and purified naturally 
occurring autoantibodies against PrP from IVIG [27]. These autoantibodies are similar to 
anti-Aβ antibodies [24, 28] that blocked PrP fibril formation and PrP neurotoxicity. 
Importantly, autoantibodies with complete human sequences are able to overcome the 
inflammatory side-effects generated by active immunization or humanized monoclonal 
antibodies during the chronic therapy. It was reported that two humanized antibodies against 
PrP95–105 might be proapoptotic in the hippocampus [29]. Interestingly enough, prion 
autoantibodies had a high affinity for PrPSc, and protected against neurotoxic effects of 
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PrPSc in neuronal cultures [27]. Autoantibodies also enhanced the uptake of PrP106–126 
A117V in microglial cells without inducing an inflammatory response [30]. Thus, IVIG and 
these autoantibodies have a large potential to be quickly and effectively used in clinical 
studies for prion disease.
While much work has been done with in vitro studies, the effect of IVIG in genetic prion 
disease and amyloid plaque pathology remains to be unclear. To address these questions, we 
treated (PrP-A116V) mice with IVIG to investigate whether IVIG could delay disease onset 
and reduce amyloid plaque formation.
Materials and Methods
Animals and Treatments
The GSS-Tg (PrP-A116V) transgenic mouse model has been described previously [4]. Mice 
that carry the mouse homolog of the GSS-associated A116V mutation expressed 
approximately six times the endogenous levels of PrP. Tg (PrP-A116V) mice developed 
progressive ataxia around 120 days and died at approximately 180 days. In this study, mice 
were bred in the laboratory of the Animal Center at Indiana University School of Medicine 
and were housed 3–5 per cage, fed with food and water ad libitum, and maintained in a 12-h 
light/dark cycle facility. Male and female mice were randomly used and administered with 
20 mg/kg IVIG (Bayer, Pittsburgh, PA, USA) [31] via intraperitoneal (IP) injection weekly 
starting from 90 days after birth until they reached the end of point (20% in body weight loss 
relative to the onset stage) or the indicated experimental time. Control mice received the 
same volume of PBS without IVIG. All animal procedures were performed in accordance 
with the protocols approved and authorized by the Institutional Animal Care and Use 
Committee at Indiana University School of Medicine.
Clinical Assessment
At the start of the treatment, mice were monitored daily for signs of prion disease, including 
gait ataxia, hunched posture, and poor righting reflex. A detailed clinical assessment scale to 
monitor the progression of disease was developed. Ataxia and mobility problems are key 
features of this mouse model and were heavily weighted in the assessment. The following 
score from 0 to 5 was used: 0 = no ataxia; 1 = no ataxia, but may show other signs such as 
walking lower to the ground; 2 = more consistent, but still with a subtle change in gait 
(wider, lower to ground), but not definitive ataxia; 3 = persistent and obvious wobble—this 
stage defined the clear onset of ataxia; 4 = stumble/loss of footing (mouse might 
occasionally start to sway (rock back and forth) when in a stationary position) and obvious 
weight loss; 5 = lethargic, very hunched, and emaciated. Mice were generally killed during 
stage 4 or 5 as they could no longer be fed, and there was a 20% in body weight loss relative 
to the onset stage. Ataxia typically developed around 120 days of age.
Histology and Immunohistochemistry
Paraffin Sections—Mice were euthanized with CO2 and slowly perfused via cardiac 
puncture with 20 ml of phosphate buffered saline (PBS) followed by 20 ml of 4% 
paraformaldehyde (PFA, Sigma-Aldrich, St. Louis, MO, USA). Brains were stored in 4% 
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PFA for 48 h and then transferred to PBS containing 0.1% sodium azide (Sigma-Aldrich, St. 
Louis, MO, USA). Brains were embedded in paraffin for cutting sections. The blocks of 
mouse cerebella were cut at similar landmarks of the cerebellum into 10-μm coronal 
sections. Paraffin slides were deparaffinized in xylene (Thermo Fisher Scientific, Waltham, 
MA, USA) and rehydrated using graded percentages of ethanol immediately before staining 
[32, 33].
Thioflavin S Staining—Sections were stained with 0.05% thioflavin S (Sigma-Aldrich, 
St. Louis, MO, USA) for detection of PrP amyloid plaque deposits and with 6-diamidino-2-
phenyl-indole, dihydrochloride (DAPI, Vector, Burlingame, CA, USA) to visualize nuclei. 
Slides were observed using a fluorescence microscope. Positive plaques were counted in 
nine sections (spaced 210 μm apart) from each cerebellum. The total surface area of plaque 
deposit was measured using ImageJ and expressed as a percentage of the total surface of the 
cerebellum.
Terminal Deoxynucleotidyl Transferase-Mediated Biotinylated UTP Nick End 
Labeling—DNA fragmentation was assessed with terminal deoxynucleotidyl transferase-
mediated biotinylated UTP nick end labeling (TUNEL) apoptosis detection kit 
(MilliporeSigma, Burlington, MA, USA), following the manufacturer’s instruction. Briefly, 
sections were incubated with proteinase K for 30 min at 37 °C. After incubation with a 
reaction mixture containing biotin-dUTP and terminal deoxynucleotidyl transferase (TdT) 
for 60 min, sections were incubated with avidin–FITC solution for 30 min at 37 °C in the 
dark. The fixed sections were incubated with 5 μg/ml DNase I for 60 min at 37 °C before 
labeling as positive control. For nuclear staining, air dried sections were mounted with 
mounting medium with DAPI. Sections were observed under a fluorescence microscope. 
The apoptosis was determined by percentage area of TUNEL-positive signal relative to the 
area of DAPI stain in each cerebellar section using ImageJ [32, 34].
Immunofluorescence of NeuN—Brain sections were first TUNEL stained with the 
proteinase K step eliminated blocked with 2% BSA in PBS for 1 h, and then incubated with 
rabbit anti-NeuN antibody (1500) (MilliporeSigma, Burlington, MA, USA) overnight. Alexa 
Fluor 647 chicken anti-rabbit IgG (H+L) (Life Technologies, Grand Island, NY, USA) was 
used as secondary antibody. Results were visualized by a fluorescence microscopy.
Immunofluorescence of GFAP and Iba1—Brain sections were incubated with rabbit 
anti-ionized calcium-binding adapter molecule 1 antibody (1:2000, Abcam, Cambridge, 
MA, USA) or mouse anti-glia fibrillary acidic protein (GFAP, 1:1000, MilliporeSigma, 
Burlington, MA, USA) followed by an alexa fluo 488 anti-rabbit or mouse IgG (Invitrogen, 
Carlsbad, CA, USA). Results were visualized under the fluorescence microscope [33].
Statistical Analysis
Statistical analyses of the differences between groups were carried out by a one-way 
ANOVA with post hoc comparisons by Dunnett’s test. All data are expressed as mean ± SD. 
Differences between two means were considered significant when p was equal or less than 
0.05.
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IVIG Delayed Disease Onset and Improves Clinical Phenotype of TG (PrP-A116V) Mice
TG (PrP-A116V) exhibited normal behavior and activity before disease onset. They began to 
display early signs of gait ataxia, the primary manifestation of GSS, around 4 months old. 
Mice around 60 days after birth showed higher levels of disability and lower survival rate 
[4].
We developed a scale scoring system that ranges from 0 (no disease) to 5 (terminal) to 
investigate the effect of IVIG on the disease onset, progression, and duration. The disease 
onset was defined as score 3, when ataxia was persistent and obviously present (see 
“Materials and Methods” for details of the ataxia assessment). Mice were generally killed 
during stage 4 or 5, as they could no longer be fed, and there was a 20% body weight loss 
from the onset stage. The mean age at disease onset of vehicle-treated control mice was 
116.9 ± 5.1 days (Fig. 1a). There was minimal difference between controls and untreated TG 
(PrP-A116V) mice (data not shown), suggesting that the stress of injection and handling did 
not affect disease onset. The mean age of onset was 130.2 ± 7.6 days in 20 mg/kg IVIG-
treated mice, which is a significant delay (11.4%) as compared to the onset of control mice 
(p < 0.05).
To assess the effect of IVIG on disease progression of Tg (PrP-A116V) mice, we calculated 
the average disability score of mice beginning at 100 days until 190 days when the majority 
of vehicle-treated mice were dead. A significant improvement in disability score was present 
at most time points, indicating that IVIG shifted the disability curve to the right (Fig. 1b). 
This data was also presented as bar graphs that displayed the percentage of mice within each 
clinical disability stage at each time point (Fig. 1c–d). Throughout the observation period, 
IVIG-treated mice showed lower disability scores as compared to control mice (Fig. 2c–d).
IVIG Elongated Survival of Tg (PrP-A116V) Mice
Tg (PrP-A116V) mice were euthanized at the terminal clinical stage of disease (end of stage 
4, beginning of stage 5) when mice became severely disabled and more than 20% of its body 
weight was lost. To determine whether IVIG delayed death in Tg (PrP-A116V) mice, 
survival time among the IVIG-treated mice and control mice was compared and survival 
curves for each group were plotted in Fig. 2a. A significant (p < 0.05) improvement in 
survival time was present in mice that received IVIG, indicating that IVIG shifts the survival 
curve to the right. By comparing the mean age at death of IVIG-treated mice and control 
mice, a similar relationship was found. IVIG significantly delayed the mean age at death to 
191 ± 12.3 days compared to 179 ± 18.2 days for the control group (Fig. 2b).
IVIG Inhibited PrP Amyloid Plaque Formation in Tg (PrP-A116V) Mice at 120 Days of Age
Deposition of thioflavin S-positive PrP amyloid plaques in the cerebellum is the 
pathognomonic feature of GSS in humans and the most prominent histopathological feature 
in Tg (PrP-A116V) mice [4]. The mean age at disease onset was 116.9 ± 5.1 days in control 
and 130.2 ± 7.6 days in IVIG-treated mice. In order to determine whether the IVIG-induced 
delayed onset was related to the reduction in PrP plaque deposition, we compared the 
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thioflavin S-positive plaque burden within the cerebellum of mice from both IVIG-treated 
and control mice at 120 days of age. The area of thioflavin S staining per total area, as a 
fraction of the total area of the cerebellar section, was determined using ImageJ and plotted 
as the relative plaque burden by normalizing each group to the control group. In mice 
receiving IVIG, almost no plaques were detected in sections examined (100 ± 35 vs. 0.1 
± 0.02%, n = 3/group, p < 0.05, Fig. 3).
We also measured the plaque burden within the cerebella of mice at the terminal stages of 
disease. Control mice at the terminal stage showed an approximately fivefold increase in the 
plaque burden, as compared to control mice at 120 days of age (525.5 ± 212.1%). However, 
as expected, there was no difference in the plaque burden between IVIG-treated mice and 
control mice at the terminal stage of disease (100 ± 41.1 vs. 99.8 ± 48.9%, n = 3/group, Fig. 
4).
IVIG Attenuated Neuronal Apoptosis in Tg (PrP-A116V) Mice at 120 Days of Age
IVIG treatment was shown to reduce Aβ-induced neuronal apoptosis [35]. Here, we 
investigated whether IVIG treatment also reduces neuronal apoptosis in Tg (PrPA116V) 
mice. Cerebellar tissues were stained with TUNEL and NeuN together to assess neuronal 
apoptosis. Similar to studies on PrP amyloid deposition, we examined mice at 120 days of 
age. Interestingly, TUNEL-positive nuclei were almost fully associated with the NeuN-
positive nuclei, indicating that the neuronal apoptosis observed in Tg (PrPA116V) mice at 
120 days of age occurred mainly in neuronal cells (Fig. 5a). The fraction of apoptotic 
neurons was also estimated as the TUNEL-positive signal relative to the signal of DAPI-
stained nuclei within each cerebellar tissue section. In control mice, the fraction of apoptotic 
neurons was 0.48 ± 0.20% (n = 3) as compared to 0.11 ± 0.02% (n = 3) in IVIG-treated mice 
(Fig. 5b, c), suggesting that IVIG significantly reduced neuronal apoptosis in Tg 
(PrPA116V) mice at 120 days of age. Consistent to amyloid deposition data, at the terminal 
stage of disease, neuronal apoptosis was increased to 0.72 ± 0.18% in control mice as 
compared to 0.66 ± 0.13% in IVIG-treated mice, suggesting IVIG did not affect neuronal 
apoptosis at late stage of disease (Fig. 5d).
IVIG Did Not Affect Glial Activation in Tg (PrP-A116V) Mice
Glial cell activation was also assessed by using immunohistochemical analyses (Fig. 6). 
There were similar levels of GFAP immunoreactivity between vehicle-treated controls and 
IVIG treatment mice at terminal stage (Fig. 6a, b). The number of GFAP-positive astrocytes 
per section was 107.3 ± 47.9 in the vehicle-treated group and 130.4 ± 31.0 in IVIG-treated 
mice (Fig. 6b). Furthermore, microglia stained with Iba1 was performed in the cerebellar 
paraffin-embedded sections and no changes in levels of microglial immunoreactivity 
between vehicle-treated controls and IVIG-treated mice at terminal stage were observed 
(Fig. 6c, d). The number of Iba1-positive microglial cells per section was 57.4 ± 8.9 in the 
vehicle-treated group and 62.3 ± 20.1 in IVIG-treated mice (Fig. 6d).
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IVIG was found to contain antibodies against Aβ peptides [21] and suggested to be 
beneficial in AD treatments [22]. However, a recent multicenter double-blinded phase III 
study of 390 subjects, called the Gammaglobulin Alzheimer’s Partnership (GAP), did not 
meet primary endpoints of slowing cognitive and functional decline [36]. Interestingly, 
results obtained from this study continued to support IVIG’s positive safety profile and 
showed potentially beneficial effects for pre-specified moderate AD and apoE4 carrier 
subgroups. Hence, the IVIG treatment for AD is still of considerable interest in the field and 
there remains the opportunity for testing the extent to which optimized doses of IVIG 
delivered early enough in the AD trajectory might yet prove beneficial for modifying disease 
progression [37]. In this study, we tested IVIG for the treatment of prion diseases such as 
GSS since not like Aβ with an unclear role in AD pathogenesis, the PrPSc aggregates in 
affected brain areas were thought to directly lead to neuronal dysfunction and neuronal 
death, which lead to clinical symptoms [3, 5, 6] and prion autoantibodies in IVIG had a high 
affinity for PrPSc, and protected against neurotoxic effects of PrPSc in neuronal cultures [27]. 
As expected, we showed that chronic treatments of Tg (PrP-A116V) mice with IVIG 
significantly delayed disease onset (14 days delay, 11%), reduced disability, and improved 
survival in these mice. These improvements were consistent with the reductions of PrP 
amyloid plaque deposition in the mouse brain and neuronal apoptosis at disease onset. IVIG 
induced such effects when it was administered weekly starting at 90 days after birth. 
Interestingly, although it elongated survival of GSS mice, IVIG did not significantly 
elongate the survival time post disease onset. This suggests that IVIG might be the one in 
humans in which affects the latency period for the prionrelated disease because people can 
usually develop prion disease up to 30 years after first being exposed to it. In this study, the 
neuroprotective effect induced by peripherally injected IVIG was modest due to its poor 
penetration ability through the blood-brain barrier (BBB) [34]. It was quite possible that 
IVIG could markedly suppress prion replication and infectivity in the peripheral immune 
system such as the spleen to slow disease onset; however, because IVIG had limited levels of 
accumulation in the brain, brain prion replication and infectivity could not be inhibited so 
disease pathogenesis eventually initiated. Our findings may also explain the data obtained 
from the immunization studies using the genetic prion model, which showed that only 
disease onset could be completely stopped by the antibody treatment [38]. Similar to our 
case, anti-PrP antibodies could only suppress pathogenic events occurring in the peripheral 
immune system but not in the brain system. Importantly, not like inoculation prion models 
generated from the exogenous inoculated pathogen, PrPSc, genetic prion diseases initially 
resulted from endogenous expression and accumulation of mutant prion in both peripheral 
and CNS systems. Therefore, peripheral immunotherapies including the IVIG treatment 
could not be used in genetic prion diseases since after the disease onset, the amount of IVIG 
in the brain was too low [39] to inhibit further pathological development of PrPSc. Evidence 
from our study strongly supports this hypothesis by showing there were no effects on brain 
amyloid deposition, neuronal apoptosis, and glial activation in IVIG-treated mice at the 
terminal stage of disease as compared to control mice.
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Thus, the key to elongating patients’ lives who have genetic prion diseases including GSS 
would be to determine certain brain levels of IVIG by inhibiting brain prion replication. We 
believe the efficacy of IVIG against genetic prion diseases can be significantly improved if 
IVIG is directly administered into the brain. In summary, this study suggested IVIG may be 
useful to treat sporadic and genetic prion disorders. However, it is necessary to develop a 
better delivery method for IVIG to largely improve its efficacy in the genetic prion disorders 
including GSS.
Also, it should be noted that the extent to which endogenous anti-PrP antibodies in IVIG 
plays a role in delaying GSS disease onset remains unclear since in our unpublished data, 
after removing anti-PrP antibodies by using the PrP affinity column, we did not find that 
IVIG-induced protective effects were markedly reduced. Thus, a further study is required to 
investigate the exact molecular mechanism(s) underlying IVIG-induced protection against 
PrPSc toxicity.
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IVIG delays disease onset and progression in Tg (PrP-A116V) mice. a Age of disease onset 
(stage 3) of Tg (PrP-A116V) mice treated with PBS or IVIG at 20 mg/kg [31], beginning at 
90 days of age. b Disability scores of Tg (PrP-A116V) mice plotted over time. Animals 
were assessed twice weekly and scored according to a disability scale that range from 0 to 5, 
until they were euthanized. c and d The bars represent the percentage of Tg (PrP-A116V) 
mice within each stage of disease at the indicated time point. Data represent mean ± SD, n = 
34/group, *p < 0.05, ***p < 0.001
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IVIG elongates survival of Tg (PrP-A116V) mice. a Kaplan-Meier survival curve of mice 
treated with PBS or IVIG once per week, beginning at 90 days of age. b Age at death of Tg 
(PrP-A116V) mice treated with PBS or IVIG. Data represent mean ± SD, n = 34/group, *p < 
0.05
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IVIG inhibits PrP amyloid plaque deposition in Tg (PrP-A116V) mice at onset stage. a 
Representative cerebellar sections stained with thioflavin S at 120 days old Tg (PrP-A116V) 
mice (onset stage) treated with PBS (control) or IVIG. b Quantification of amyloid load in 
cerebella: nine coronal sections per cerebellum stained with thioflavin S were used to 
quantify PrP amyloid plaques. Nuclei were stained with DAPI. All sections were visualized 
by fluorescence microscopy and data were expressed as the relative plaque burden, by 
normalizing each group to the control group. Data represent mean ± SD, n = 3/group, *p < 
0.05
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IVIG affects PrP amyloid plaque deposition in Tg (PrP-A116V) mice at terminal stage. a 
Representative cerebellum sections from Tg (PrP-A116V) mice (terminal stage) treated with 
PBS or IVIG. Sections were stained with thioflavin S to detect PrP amyloid plaques. Nuclei 
were stained with DAPI. Sections were visualized by fluorescence microscopy. b The area 
of thioflavin S staining was determined using ImageJ and plotted as the relative plaque 
burden. Data represent mean ± SD, n = 3/group, *p < 0.05
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IVIG affects apoptosis in Tg (PrP-A116V) mice. TUNEL (green) and DAPI staining of 
representative cerebellum sections from 120 days old and terminal stage Tg (PrP-A116V) 
mice treated with PBS or IVIG. a Representative cerebellum sections from 120 days Tg 
(PrP-A116V) mice treated with PBS or IVIG. Apoptosis cells were estimated as the 
TUNEL-positive signal (green) was associated within NeuN-positive neurons (red). b 
TUNEL-positive nuclei (green) relative to the signal of DAPI-stained nuclei within each 
cerebellar section. c The fraction of apoptosis cells from 120 days mice. d The fraction of 
apoptosis cells from terminal stage mice. Data represent mean ± SD, n = 3/group, *p < 0.05
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IVIG does not affect astrocyte and microglial activation in Tg (PrP-A116V) mice. Mouse 
anti-GFAP and anti-Iba1 antibody staining of cerebellar sections from terminal stage Tg 
(PrP-A116V) mice treated with PBS or IVIG. a Representative GFAP-stained cerebellum 
sections from terminal stage mice treated with PBS or IVIG. b Numbers of GFAP+ cells 
from terminal stage mice. c Representative Iba1 cerebellum sections from terminal stage 
mice treated with PBS or IVIG. d Numbers of Iba1+ cells from terminal stage mice. Data 
represent mean ± SD, n = 3/group
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